← The Wire
FATENasdaq
FATE THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · CIK 1434316
Develops off-the-shelf cellular immunotherapies from engineered stem cells for broad patient access
red 8-K · 90d
$240M
Market cap
$2.42
Last close
+15.2%
1D
+12.6%
5D
5.9M
Volume
Price · last 39 sessions+34.4%
May 4L $1.73 · H $2.84Jun 29
249
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA14AApr 24, 2026DEFA14ADEFA14AApr 17, 2025DEFA14ADEFA14AApr 26, 2024DEFA14ADEFA14AApr 21, 2023DEFA14ADEFA14AApr 25, 2022DEFA14ADEFA14AApr 21, 2021DEFA14ADEFA14AMar 20, 2020DEFA14ADEFA14AApr 8, 2019DEFA14ADEFA14AMar 16, 2018DEFA14ADEFA14AMar 22, 2017DEFA14ADEFA14AMar 30, 2016DEFA14ADEFA14AApr 2, 2015
Insider Activity
In the 90 days to Jan 9, 2026: 2 sold $17K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 9, 2026 | Tahl CindySee Remarks | Sell | 10,589 | $1.06 | $11K |
| Jan 9, 2026 | Valamehr BahramPresident and CEO | Sell | 5,190 | $1.07 | $6K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance